Evidence map›Paper›PMID 34571211›Full record

ArticleTransplantation and cellular therapy2021

Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic.

Duncan Purtill, Cheryl Hutchins, Glen Kennedy, Andrea McClean, Chris Fraser, Peter J Shaw, Paul Chiappini, Helen Tao, David Df Ma, Karieshma Kabani and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Duncan PurtillBlood and Marrow Transplant Program, Fiona Stanley Hospital, Perth, Australia; Bone Marrow Transplant Laboratory, PathWest Laboratory Medicine WA, Perth, Australia. Electronic address: duncan.purtill@health.wa.gov.au.
Cheryl HutchinsRoyal Brisbane and Women's Hospital, Brisbane, Australia.
Glen KennedyRoyal Brisbane and Women's Hospital, Brisbane, Australia.
Andrea McCleanRoyal Brisbane and Women's Hospital, Brisbane, Australia.
Chris FraserQueensland Children's Hospital, Brisbane, Australia.
Peter J ShawBlood Transplant and Cell Therapies Program, The Children's Hospital at Westmead, Sydney, Australia; Speciality of Child and Adolescent Health, The University of Sydney, Sydney, Australia.
Paul ChiappiniBone Marrow Transplant Laboratory, PathWest Laboratory Medicine WA, Perth, Australia.
Helen TaoDepartment of Haematology and Bone Marrow Transplantation, St. Vincent's Hospital, Sydney, Australia.
David Df MaDepartment of Haematology and Bone Marrow Transplantation, St. Vincent's Hospital, Sydney, Australia; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Kensington, Australia.
Karieshma KabaniRoyal Prince Alfred Hospital, Sydney, Australia.
Lijun BaiCellular Therapeutic Laboratory, Northern Blood Research Centre, Royal North Shore Hospital, Sydney, Australia.
Matthew GreenwoodRoyal North Shore Hospital, Sydney, Australia; The University of Sydney, Sydney, Australia.
Ashish BajelClinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Elizabeth O'FlahertyClinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia.
David J CurtisAlfred Health, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.
Leanne PurinsCellular Therapies Laboratory, SA Pathology, Adelaide, Australia.
Travis PereraWellington Blood and Cancer Centre, Wellington Hospital, Wellington, New Zealand.
Sarah TanDepartment of Haematology, Auckland District Health Board, Auckland, New Zealand.
Andrew ButlerSouth Island Blood and Marrow Transplant Program, Christchurch Hospital, Christchurch, New Zealand.
Ken MicklethwaiteBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, Australia; Blood Transplant and Cell Therapies Laboratory, NSW Health Pathology ICPMR Westmead, Sydney, Australia.
Vicki AntonenasBlood Transplant and Cell Therapies Laboratory, NSW Health Pathology ICPMR Westmead, Sydney, Australia.
David GottliebBlood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
Nada HamadDepartment of Haematology and Bone Marrow Transplantation, St. Vincent's Hospital, Sydney, Australia; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Kensington, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Changes to donor availability, collection center capacity, and travel restrictions during the early phase of the COVID-19 pandemic led to routine cryopreservation of most unrelated donor products for hematopoietic transplantation prior to the recipient commencing the conditioning regimen. We investigated the effect of this change on unrelated donor product quality and clinical outcomes. Product information was requested from transplantation centers in Australia and New Zealand and clinical outcome data from the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR). In total, 191 products were collected between April 1, 2021, and September 30, 2021, and most (74%) were from international collection centers. Median post-thaw CD34 recovery was 78% (range 25% to 176%) and median post-thaw CD34 viability was 87% (range 34% to 112%). Median time to neutrophil recovery was 17 days (interquartile range 10 to 24 days), and graft failure occurred in 6 patients (4%). These clinical outcomes were similar to those of "fresh" unrelated donor transplants reported to the ABMTRR in 2019. However, recipient transplantation centers reported problems with 29% of products in the form of damage during transit, low cell dose, inadequate labeling, missing representative samples, or missing documentation. These problems were critical in 7 cases (4%). At last follow-up, 22 products (12%) had not been infused. Routine cryopreservation of unrelated donor hemopoietic progenitor cell products has enabled safe continuation of allogeneic transplant services during the COVID-19 pandemic. However, practices for product tracing, documentation, and transportation can be optimized, and measures to reduce the incidence of unused unrelated donor product are required.

Indexed as

COVID-19CryopreservationHematopoietic Stem CellsHumansPandemicsSARS-CoV-2COVID-19CryopreservationDonorEngraftmentStem cell quality

Identifiers

PMID34571211
PMCPMC10202757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.